Capmatinib is the first generation targeted drug

Capmatinib (Capmatinib) is a second-generation targeted drug. Targeted drugs refer to drugs that treat cancer by specifically acting on specific molecules or signaling pathways in cancer cells. Targeted drugs are divided into different generations according to the chronological order of their development and application. The first generation of targeted drugs mainly targets some specific receptors or signaling pathways on the surface of tumor cells, such as EGFR inhibitors, HER2 inhibitors, etc. These drugs have achieved certain clinical success, but there are also problems such as drug resistance and side effects.

The second generation of targeted drugs is further improved and optimized on the basis of the first generation of drugs, targeting new targets or signaling pathways. This type of drug has higher selectivity and potency, effectively inhibiting the growth and spread of tumor cells. Capmatinib is a second-generation targeted drug.

Capmatinib is a targeted chemotherapy drug. It is different from traditional chemotherapy drugs, which attack all dividing cells, destroying both healthy cells and cancer cells. Capmatinib is used to treat non-small cell lung cancer (NSCLC) that has spread (metastasized) in adults whose tumors have mutations that cause mesenchymal epithelial transition (MET) exon 14 skipping. Capmatinib targets non-small cell lung cancer cells with a mutated MET gene lacking exon 14, a mutation associated with increased cancer cell growth. Capmatinib works by blocking the signals from these cells that drive cancer cell growth.

In summary, capmatinib, as a second-generation targeted drug, has higher selectivity and efficacy and can be used to treat specific cancer types or individualized characteristics. However, as with all drugs, the use of capmatinib needs to be based on physician advice and guidance, and requires comprehensive consideration of the patient's condition and the trade-off between efficacy and safety.